Ashvattha Therapeutics LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ashvattha Therapeutics LLC
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Finance Watch: HilleVax, Belite Bio Launch First Two Biopharma IPOs In Q2
Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics.
- Radiopharmaceuticals, Contrast Agents
- Other Names / Subsidiaries
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.